Home / Market News / $XRTX
benzinga Corporate Catalyst Impact 75/100 ● positive

XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why

Oct 9, 2026, 6:50 AM UTC · Primary ticker $XRTX

XORTX Therapeutics announced it is preparing a Clinical Trial Application (CTA) with Health Canada for its gout drug candidate, XRx-026, which is expected to accelerate clinical data delivery and support a future FDA New Drug Application. This news led to a significant after-hours stock jump, reflecting investor optimism about the drug's development progress and potential commercialization.

XORTX Therapeutics announced a significant step forward for its gout drug candidate, XRx-026, by preparing a Clinical Trial Application (CTA) with Health Canada. This move is crucial as it's expected to expedite the collection of key clinical data, which will then support a planned New Drug Application (NDA) with the FDA. The market reacted positively, with XRTX stock jumping over 22% after hours, indicating investor confidence in the drug's development pathway and potential for future commercialization. While the company also noted increased interest from potential commercialization partners, no agreements have been made, presenting both an opportunity for future growth and a risk if discussions don't materialize. This development is a short-term catalyst for the stock, but long-term success hinges on positive clinical trial results and successful regulatory approvals.

$XRTX positive Advancing gout drug to clinical trials
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.